Evidence map›Paper›PMID 19383174›Full record

ArticleMolecular cancer2009

Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells.

Rod Balhorn, Saphon Hok, Sally DeNardo, Arutselvan Natarajan, Gary Mirick, Michele Corzett, Gerald Denardo

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Development and Prospects of Furin Inhibitors for Therapeutic Applications.International journal of molecular sciences · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rod BalhornUniversity of California, Department of Applied Science, Hertz Hall, Livermore, CA 94551, USA. rodbalhorn@hughes.net
Saphon Hok
Sally DeNardo
Arutselvan Natarajan
Gary Mirick
Michele Corzett
Gerald Denardo
University of California Davis Medical Center · USLawrence Livermore National Laboratory · US

Funding

TREATMENT OF B CELL MALIGNANCIES.P01CA047829 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI DENARDO, GERALD L · 1988 to 2006
$10.0M
NCI NIH HHS P01 CA047829NCI NIH HHS P01-CA47829
6 · The paper itself

Abstract

backgroundA variety of arginine-rich peptide sequences similar to those found in viral proteins have been conjugated to other molecules to facilitate their transport into the cytoplasm and nucleus of targeted cells. The selective high affinity ligand (SHAL) (DvLPBaPPP)2LLDo, which was developed to bind only to cells expressing HLA-DR10, has been conjugated to one of these peptide transduction domains, hexa-arginine, to assess the impact of the peptide on SHAL uptake and internalization by Raji cells, a B-cell lymphoma.

resultsAn analog of the SHAL (DvLPBaPPP)2LLDo containing a hexa-arginine peptide was created by adding six D-arginine residues sequentially to a lysine inserted in the SHAL's linker. SHAL binding, internalization and residualization by Raji cells expressing HLA-DR10 were examined using whole cell binding assays and confocal microscopy. Raji cells were observed to bind two fold more 111In-labeled hexa-arginine SHAL analog than Raji cells treated with the parent SHAL. Three fold more hexa-arginine SHAL remained associated with the Raji cells after washing, suggesting that the peptide also enhanced residualization of the 111In transported into cells. Confocal microscopy showed both SHALs localized in the cytoplasm of Raji cells, whereas a fraction of the hexa-arginine SHAL localized in the nucleus.

conclusionThe incorporation of a hexa-D-arginine peptide into the linker of the SHAL (DvLPBaPPP)2LLDo enhanced both the uptake and residualization of the SHAL analog by Raji cells. In contrast to the abundant cell surface binding observed with Lym-1 antibody, the majority of (DvLPBaPPP)2LArg6AcLLDo and the parent SHAL were internalized. Some of the internalized hexa-arginine SHAL analog was also associated with the nucleus. These results demonstrate that several important SHAL properties, including uptake, internalization, retention and possibly intracellular distribution, can be enhanced or modified by conjugating the SHALs to a short polypeptide.

Indexed as

ArginineBinding SitesCell Line, TumorCell NucleusHeterocyclic Compounds, 1-RingHLA-DR AntigensHLA-DR Serological SubtypesHumansLigandsLymphoma, B-CellMicroscopy, ConfocalOligopeptidesPeptidesArginineHeterocyclic Compounds, 1-RingHLA-DR10 antigenHLA-DR AntigensHLA-DR Serological SubtypesLigandsOligopeptidesPeptides

Identifiers

PMID19383174
PMCPMC2680800
OpenAlexW2157281566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.